Clinical trials located in

Magdeburg

Magdeburg city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Magdeburg, the capital city of Saxony-Anhalt, Germany, boasts a rich history dating back over 1,200 years. It is renowned for the Magdeburg Cathedral, a masterpiece of Gothic architecture and the oldest Gothic structure in Germany. The city played a pivotal role during the Protestant Reformation as the site of the Magdeburg Confession. Additionally, it is home to the Green Citadel, one of the last architectural works of Friedensreich Hundertwasser, showcasing a unique blend of colorful design and ecological features. Magdeburg also pioneered the Magdeburg Hemispheres experiment, demonstrating the power of atmospheric pressure in the 17th century.

  • CT-EU-00120654

    Study of Barzolvolimab (CDX-0159) in Adult Patients with Eosinophilic Esophagitis

    This clinical study involves patients with Eosinophilic Esophagitis (EoE), a condition where a type of white blood cell, called eosinophils, builds up in the lining of the esophagus. This can lead to difficulty swallowing and other issues. The therapy being tested is barzolvolimab (CDX-0159).

    The goal of the study is to test the effectiveness and safety of barzolvolimab in adults with active EoE. There are two main groups in this study: one will receive barzolvolimab, and the other will receive a placebo, followed by barzolvolimab.

    Participants will receive treatment through subcutaneous (under the skin) injections every four weeks for 24 weeks. In the barzolvolimab group, patients will get 300 mg of the medication from the start. In the other group, patients will receive a placebo for the first 16 weeks and then switch to barzolvolimab for the remaining 8 weeks.

    The study will look at changes in the number of eosinophils and other cells in the esophagus, as well as symptoms like difficulty swallowing. Side effects and other health changes will be monitored throughout the study.

    • Placebo
    • barzolvolimab
  • Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • Study of the new oral drug LY3871801 for rheumatoid arthritis

    The aim of this study is to test a new drug called LY3871801 for people suffering from moderate to severe rheumatoid arthritis. The main goal is to see if this new drug can help reduce disease activity and improve symptoms better than a placebo. In the first part of the study, doctors will check how much the Disease Activity Score changes after 12 weeks of taking LY3871801 or a placebo. Then, in the second part, they will look at what percentage of patients experience significant improvement, defined as achieving an ACR50 response, which means reducing symptoms of rheumatoid arthritis by 50% or more. Both the real drug and the placebo will be taken by mouth.

    • placebo
    • LY3871801
  • Evaluating new medication in congenital hyperinsulinism treatment

    This clinical trial is focused on testing a new treatment called HM15136 for individuals aged 2 years and older who have Congenital Hyperinsulinism (CHI). CHI is a condition that causes persistent low blood sugar levels due to excessive insulin production. The study aims to find out how safe and effective HM15136 is when used alongside standard treatments that participants are already receiving for CHI.

    HM15136 will be given as a subcutaneous (under the skin) injection once a week for 8 weeks. The trial will look into how well the body tolerates this medication, any side effects that might occur, and how the body processes the drug. Additionally, the study will assess the effectiveness of HM15136 in managing blood sugar levels in participants.

    The safety of the participants will be closely monitored throughout the study, focusing on any adverse events, serious adverse events, and changes in clinical laboratory tests. The trial will also measure the highest concentration of the drug in the bloodstream and how long it takes to reach this peak level after administration.

    This study is an opportunity for individuals with CHI to potentially improve their condition and contribute to medical research in finding new treatments for this rare disease.

    • HM15136
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    • Mabthera
    • Ifosfamide
    • Polatuzumab vedotin
    • Etoposide
    • Carboplatin
  • Comparing treatments for new Large B-cell lymphoma patients

    The trial aims to analyze and compare two drug treatments for people who have a large B-Cell Lymphoma, a kind of cancer that affects a certain type of white blood cells, and have not yet started their treatment. The first treatment is a combination of glofitamab, polatuzumab vedotin, and other common drugs used for this condition: rituximab, cyclophosphamide, doxorubicin, and prednisone. The second treatment is the same, but doesn’t include the glofitamab. The goal is to understand which treatment is more effective and safer for the patient.

    • Prednisone
    • Polatuzumab vedotin
    • Glofitamab
    • Doxorubicin
    • Cyclophosphamide
    • Rituximab
  • Investigating safety and effects of new medicine in overweight diabetic patients

    This trial is exploring AZD9550, a new drug in development for treating non-alcoholic steatohepatitis (NASH), a liver disease often seen in overweight or obese individuals with type 2 diabetes mellitus (T2DM). The study will involve 88 participants aged 18 to 65 who are overweight or obese and living with T2DM. The study is divided into four parts, with varying doses of AZD9550 administered subcutaneously (under the skin) to evaluate its safety, how well it is tolerated, and how it affects the body. The trial will also compare the effects of AZD9550 to a placebo (a substance with no therapeutic effect) to benchmark its safety and tolerability.

    • AZD9550- new medication for non-alcoholic steatohepatitis and metabolic dysfunction-associated steatohepatitis
  • Testing orforglipron for obesity & type 2 diabetes

    A drug called Orforglipron is being tested. This study is for adults who are overweight or have a disease called type 2 diabetes. The purpose of this study is to see if this medicine can safely help people lose weight. Some patients will receive orforglipron once a day, the rest will receive a placebo. All patients will be monitored to see how their weight changes. The study will last 77 weeks.

    • Orforglipron
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    • GSK3511294 (Depemokimab)
    • Mepolizumab
    • Benralizumab
  • Effects of new treatment on nonalcoholic steatohepatitis

    This study tests a new medicine, AZD2693, through skin injections in adults with a special type of liver disease called non-cirrhotic non-alcoholic steatohepatitis (NASH) with fibrosis. Participants, who have a specific genetic risk (PNPLA3 148M allele), will either get AZD2693 or a placebo. The study, involving 180 people, checks if AZD2693 can help reduce liver problems without causing further damage. It runs for about a year, looking at liver health and any side effects from the medicine.

    • AZD2693- new potential medication for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
  • Secukinumab study for maintaining remission in axial spondyloarthritis

    The aim of this study is to see if a drug called Secukinumab can maintain remission in people with non-radiographic axial spondyloarthritis (a type of spondylitis). Remission means that there is no or very little disease in the body. To determine whether a person is in remission, we use a special scoring system that looks at various symptoms of arthritis and a blood test for a protein associated with inflammation (C-reactive protein, or CRP). The aim of the study is to see whether people who stop taking Secukinumab will experience an exacerbation (worsening of the disease) and how long it takes for this to happen. The study will last just over two years.

    • Secukinumab
  • Pemigatinib in the treatment of cholangiocarcinoma

    This study focuses on comparing the impact and safety of two treatments: Pemigatinib and a chemotherapeutic combination of Gemcitabine and Cisplatin. These treatments are being tested on people who have an advanced form of liver cancer, cholangiocarcinoma, which cannot be removed by surgery or has spread to other parts of the body, and is associated with a particular genetic change known as FGFR2 rearrangement. The aim is to examine the effectiveness of Pemigatinib in comparison to the chemotherapy combination of Gemcitabine and Cisplatin. Measurements of success will be based on how much the cancer shrinks, the duration of response to treatment, as well as any side effects encountered.

    • Pemigatinib
    • Gemcitabine
    • Cisplatin
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Comparing abelacimab and apixaban treatments for blood clots in cancer patients

    This research study is looking at how two different medicines, abelacimab and apixaban, can help people with a severe medical problem called Cancer Associated Thrombosis (CAT). CAT happens when blood clots form inside the veins (a condition called Venous Thromboembolism or VTE) in people with cancer. These blood clots can cause other serious health issues. In this study, the researchers will see if abelacimab (which is given monthly) is as good as apixaban if not better (which you take twice a day every day) for six months. And then look at whether the blood clots come back, if any bleeding happens, and if patients had to stop treatment.

    • Abelacimab
    • Apixaban
  • Study on the safety and effectiveness of luspatercept in myelodysplastic syndromes patients

    The aim of this study is to test a drug called Luspatercept in people with lower-risk myelodysplastic syndrome (MDS) characterized by ring sideroblasts (MDS-RS), a condition in which the body does not produce enough healthy blood cells. The main aim of the study is to see if Luspatercept can help patients who require regular blood transfusions due to anemia. The study will also look at how long it takes for the medicine to work, how long it lasts, and changes in the need for blood transfusions and levels of hemoglobin (an important protein in red blood cells). The study will also measure changes in certain substances in the blood and the progression of their MDS. Finally, the study will use questionnaires to understand how patients’ lives and physical abilities have changed over time.

    • Luspatercept
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab

See more clinical trials in other cities in Germany:

.